Plant-Derived Anti-Tumor Agents in Preclinical Development

Exploring the Potential of Plant-Derived Compounds for Cancer Treatment

Abstract

Various normally inferred agents have been gone into clinical trials and ended because of absence of adequacy or unsatisfactory poisonous quality. It is likewise worth remembering that the advancement of successful medications, for example, paclitaxel (taxol) and the camptothecin subordinates, topotecan, and irinotecan, required 20– 30 years of devoted research and tolerance, and extensive assets, to eventually demonstrate their adequacy as clinical agents. Another case of an "old" medication of an indistinguishable vintage from taxol® and camptothecin having a probability of restoration is bruceantin which was first confined from a tree, Bruceaantidysenterica (Simaroubaceae), utilized as a part of Ethiopia for the treatment of "growth" (Cuendet and Pezzuto, 2004).